Review summary
Teaching objective: Hypertension, type 2 diabetes and kidney disease in a 49-year-old community organizer in the rural Mississippi Delta, managed at a community health center with trauma-informed care. The teaching contrast is her documented sterilization without consent: here every examination, test and procedure is explained beforehand, done only with her documented consent, with a chaperone of her choosing, and stopped or declined at her word without loss of care. The episode covers confirming hypertension with home readings under the 2025 AHA/ACC guideline, diagnosing and treating diabetes under the ADA Standards of Care 2026, kidney function and urine albumin with KDIGO, an ACE inhibitor and an SGLT2 inhibitor, a statin, retinal photographs, foot care, medication choices for cost and adherence, a community health worker on the team, a social needs screen with real resources for food, transportation and utility costs, shared decisions, and preventive care.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| October 6, 1917 | Born in Montgomery County, Mississippi. | CLM-0001 |
| 1961 | Operation for a uterine tumor, with a hysterectomy done without her knowledge or consent. | CLM-0003 |
| August 31, 1962 | Tried to register to vote; evicted from the plantation the same night. | CLM-0002, CLM-0004 |
| June 9, 1963 | Arrested and beaten in the Winona jail; lifelong injuries to her eyes, legs and kidneys. | CLM-0005, CLM-0006 |
| August 22, 1964 | Testimony before the Credentials Committee in Atlantic City. | CLM-0007 |
| early 1977 | Final hospital admission in Mound Bayou for complications of heart disease, diabetes and breast cancer. | CLM-0008 |
| March 14, 1977 | Died in Mound Bayou at 59. | CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Fannie Lou Hamer was born on October 6, 1917, in Montgomery County, Mississippi, the twentieth child of Lou Ella and James Lee Townsend, sharecroppers. She joined her family in the cotton fields at six and left school after the sixth grade, at 12, to work on the cotton plantations of the Delta. | confirmed | Fannie Lou Hamer (biography) supports Fannie Lou Hamer supports Fannie Lou Hamer (Freedom Summer, American Experience) supports HISTMED Master Roster v3 context |
| D | She worked for eighteen years as a sharecropper and timekeeper on a Delta plantation, made timekeeper because she could read and write. In 1964 she gave her home as Ruleville, in Sunflower County, Mississippi. Anchors her literacy, her rural Delta home and her work history in the modern social history. |
confirmed | Fannie Lou Hamer supports Fannie Lou Hamer: Testimony Before the Credentials Committee, Democratic National Convention, August 22, 1964 (Say It Plain) supports |
| D | In 1961, hospitalized for abdominal pain, she was found to have a uterine tumor; during the operation to remove it, a white surgeon performed a hysterectomy without her knowledge or informed consent. She later called this a "Mississippi appendectomy," a name for the sterilizations done without consent to Black women in the South. The anchor for the teaching contrast: in the modern episode every examination, test and procedure is explained in advance and done only with her documented consent, and her right to refuse is respected. Her mistrust of medical care was earned. |
confirmed | Fannie Lou Hamer (biography) supports Fannie Lou Hamer (Freedom Summer, American Experience) supports Bunch M. Why civil rights icon Fannie Lou Hamer was 'sick and tired of being sick and tired' supports Ladd D. Editor's Note: As You Vote, Recall the Blackjacks Hitting Mrs. Hamer's Back supports |
| D | On August 31, 1962, she tried to register to vote in Indianola; when she refused to withdraw her application, the plantation owner ordered her off his land and she had to leave that same night. | confirmed | Fannie Lou Hamer supports Fannie Lou Hamer: Testimony Before the Credentials Committee, Democratic National Convention, August 22, 1964 (Say It Plain) supports |
| D | On June 9, 1963, returning from a voter-registration workshop, she was arrested with other activists in Winona, Mississippi, and in the jail two Black prisoners were ordered by officers to beat her with a blackjack, as she testified the next year. Anchors the history of injury and the trauma-informed approach in the modern episode. |
confirmed | Fannie Lou Hamer: Testimony Before the Credentials Committee, Democratic National Convention, August 22, 1964 (Say It Plain) supports Remembering 1963: Fannie Lou Hamer Arrested and Beaten in Winona, Mississippi supports Beatings in Winona Jail supports |
| D | The beating left her with lifelong injuries to her eyes, legs and kidneys: permanent kidney damage, and a blood clot in her left eye with loss of vision in one eye. The anchor for the modern kidney history and the reduced vision in her left eye. The modern kidney findings are synthetic. |
confirmed | Fannie Lou Hamer (Freedom Summer, American Experience) supports Bunch M. Why civil rights icon Fannie Lou Hamer was 'sick and tired of being sick and tired' supports Remembering 1963: Fannie Lou Hamer Arrested and Beaten in Winona, Mississippi supports Barnes J. Winona marks where civil rights leader Fannie Lou Hamer was beaten inside city jail after nearly 60 years supports Turner T. Fannie Lou Hamer supports |
| D | On August 22, 1964, she testified before the Credentials Committee of the Democratic National Convention in Atlantic City about her eviction and the Winona beating. | confirmed | Fannie Lou Hamer: Testimony Before the Credentials Committee, Democratic National Convention, August 22, 1964 (Say It Plain) supports Fannie Lou Hamer (biography) supports |
| D | In her late fifties she found a lump in her left breast and did not seek care for it at first. Appeals were made to help with her mounting medical bills. In early 1977 she was admitted for the last time to the hospital in Mound Bayou, where she was treated for complications of heart disease, diabetes and breast cancer. History after the modern episode. Anchors the later diabetes and the cost barriers in the modern record; the breast cancer appears only as history and in screening. |
confirmed | Loss of an Icon (Fannie Lou Hamer Resource Center, drawing on Brooks MP, Fannie Lou Hamer: America's Freedom Fighting Woman) supports |
| D | She died on March 14, 1977, in Mound Bayou, Mississippi, at 59. Accounts of the cause differ: complications of hypertension and breast cancer, complications of heart disease and cancer, or breast cancer. History only, a decade after the modern episode. Anchors the later hypertension. |
confirmed | Turner T. Fannie Lou Hamer supports Fannie Lou Hamer (Freedom Summer, American Experience) supports Fannie Lou Hamer (biography) supports Loss of an Icon (Fannie Lou Hamer Resource Center, drawing on Brooks MP, Fannie Lou Hamer: America's Freedom Fighting Woman) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later life | active | confirmed | both_with_link | CLM-0008 |
| S | Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | active | CLM-0009 |
| S | Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigated | resolved | confirmed | active | CLM-0005, CLM-0006 |
| S | Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later life | active | confirmed | both_with_link | CLM-0009 |
| S | Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contribute | active | confirmed | active | CLM-0005, CLM-0006 |
| S | Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention) | active | confirmed | active | CLM-0008 |
| S | Food insecurity: food runs out before the end of most months | active | confirmed | active | |
| S | Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrange | active | confirmed | active | CLM-0002 |
| S | Hyperlipidemia: LDL 146 mg/dL | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6% (high) Reference Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her |
http://loinc.org · 4548-4 |
| S | 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 238 mg/dL (high) Reference Random sample; 200 mg/dL or higher with symptoms is diagnostic of diabetes |
http://loinc.org · 2345-7 |
| S | 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 73 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 88 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-03-09 | Cholesterol [Mass/volume] in Serum or Plasma | 228 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-03-09 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 146 mg/dL (high) Reference Goal below 70 mg/dL with diabetes and kidney disease |
http://loinc.org · 13457-7 |
| S | 2026-03-09 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-03-09 | Triglyceride [Mass/volume] in Serum or Plasma | 190 mg/dL (high) Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 10-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 268 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-03-09 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 3 | http://loinc.org · 96777-8 |
| S | 2026-03-23 | Albumin/Creatinine [Mass Ratio] in Urine | 96 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-05-04 | Cholesterol [Mass/volume] in Serum or Plasma | 154 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 80 mg/dL Reference Goal below 70 mg/dL with diabetes and kidney disease |
http://loinc.org · 13457-7 |
| S | 2026-05-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-05-04 | Triglyceride [Mass/volume] in Serum or Plasma | 142 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3% (high) Reference Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her |
http://loinc.org · 4548-4 |
| S | 2026-07-13 | Albumin/Creatinine [Mass Ratio] in Urine | 52 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-07-13 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 1 | http://loinc.org · 96777-8 |
| S | 2026-10-19 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9% (high) Reference Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her |
http://loinc.org · 4548-4 |
| S | 2026-10-19 | Albumin/Creatinine [Mass Ratio] in Urine | 41 mg/g (high) Reference Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) |
http://loinc.org · 9318-7 |
| S | 2026-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 mL/min/1.73 m² (low) Reference 90 or higher is normal; 60 to 89 is mildly decreased (G2) |
http://loinc.org · 98979-8 |
| S | 2026-10-19 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 1 | http://loinc.org · 96777-8 |
| S | 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 cm | 8302-2 | S |
| 2026-03-09 | Body weight | 93 kg | 29463-7 | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 35 kg/m2 | 39156-5 | S |
| 2026-03-09 | Systolic blood pressure | 164 mm[Hg] | 8480-6 | S |
| 2026-03-09 | Diastolic blood pressure | 98 mm[Hg] | 8462-4 | S |
| 2026-03-09 | Heart rate | 84 /min | 8867-4 | S |
| 2026-03-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-09 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-03-23 | Body height | 163 cm | 8302-2 | S |
| 2026-03-23 | Body weight | 92.6 kg | 29463-7 | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 34.9 kg/m2 | 39156-5 | S |
| 2026-03-23 | Systolic blood pressure | 156 mm[Hg] | 8480-6 | S |
| 2026-03-23 | Diastolic blood pressure | 96 mm[Hg] | 8462-4 | S |
| 2026-03-23 | Heart rate | 82 /min | 8867-4 | S |
| 2026-03-23 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-23 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-04 | Body height | 163 cm | 8302-2 | S |
| 2026-05-04 | Body weight | 91.8 kg | 29463-7 | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 34.6 kg/m2 | 39156-5 | S |
| 2026-05-04 | Systolic blood pressure | 136 mm[Hg] | 8480-6 | S |
| 2026-05-04 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-05-04 | Heart rate | 78 /min | 8867-4 | S |
| 2026-05-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-04 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-13 | Body height | 163 cm | 8302-2 | S |
| 2026-07-13 | Body weight | 90.9 kg | 29463-7 | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 34.2 kg/m2 | 39156-5 | S |
| 2026-07-13 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-07-13 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-07-13 | Heart rate | 76 /min | 8867-4 | S |
| 2026-07-13 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-13 | Body temperature | 36.9 Cel | 8310-5 | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-19 | Body height | 163 cm | 8302-2 | S |
| 2026-10-19 | Body weight | 90 kg | 29463-7 | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 33.9 kg/m2 | 39156-5 | S |
| 2026-10-19 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-10-19 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-19 | Heart rate | 74 /min | 8867-4 | S |
| 2026-10-19 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-19 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-09-14 | Body height | 163 cm | 8302-2 | S |
| 2026-09-14 | Body weight | 90.4 kg | 29463-7 | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 34 kg/m2 | 39156-5 | S |
| 2026-09-14 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-09-14 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-09-14 | Heart rate | 74 /min | 8867-4 | S |
| 2026-09-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-14 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Lives in Ruleville, in Sunflower County in the Mississippi Delta, with her husband; a community organizer for voting rights and for food and work in her county; formerly a sharecropper and plantation timekeeper
- S No car; rides to the health center depend on neighbors and organizing work; long distance to the nearest hospital and pharmacy
- S Irregular income from organizing work; no health insurance; uses the health center's sliding-fee scale; food runs short at the end of most months; utility bills hard to pay in summer and winter
- S Tobacco: never. Alcohol: none. No drug use
- S Strengths: deep faith, singing, leadership in her community, a wide network of neighbors and fellow organizers, and a clear sense of what she will and will not agree to
- S Says she does not trust hospitals since an operation was done to her without her consent, and wants to be told what will be done, and why, before anyone touches her
Functional status
- S Independent in daily activities; walks with a limp and aches in the legs and lower back after long days, worse since an old injury; reduced vision in the left eye; reads with the right eye
Mental status
- S Alert, direct and warm; guarded at first about examinations, relaxed once each step was explained; mood steady; PHQ-9 score 4
Allergies and medications
Allergies
- S No known allergy
Medications
- S Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal
- S Metformin extended-release 500 mg oral tablet, three tablets with the evening meal
- S Atorvastatin 40 mg oral tablet, one tablet daily
- S Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily
- S Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery
Procedures and immunizations
Procedures
- S Twelve-lead electrocardiogram, after the purpose was explained and she agreed, with a female assistant
- S Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses, with her consent
- S Ultrasound of both kidneys and the bladder at the health center, after the purpose and steps were explained and she agreed, with a female sonographer and her chosen companion present
- S Retinal photographs of both eyes in the clinic without dilating drops, with her consent
- S Advance care planning conversation, about 25 minutes
- S Screening mammogram, both breasts, after the steps were explained and she agreed, with a female technologist and the community health worker accompanying her
Immunizations
- S 2026-03-23: Pneumococcal conjugate vaccine PCV20
- S 2026-03-23: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-03-23: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
- S 2026-05-04: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2026-10-19: Influenza vaccine, inactivated, this season
- S 2026-10-19: COVID-19 vaccine, mRNA, this season
- S 2026-10-19: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1961: Operation to remove a uterine tumor, during which a hysterectomy was performed without her knowledge or informed consent; she calls it a "Mississippi appendectomy". Whether the cervix was removed is not known; no operative record is available (CLM-0003)
- D June 9, 1963: Beaten in the Winona jail, with lasting injuries: permanent kidney damage, a blood clot in the left eye with reduced vision in that eye, and injuries to her legs (CLM-0005, CLM-0006)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Every examination, test and procedure explained first and done only with her documented agreement, with a chaperone of her choosing, at every visit | 2026-10-19 | completed | Consent documented for every examination, blood draw, ultrasound, photograph, vaccine and screening test; she declined a breast and a pelvic examination, and that was respected |
| Blood pressure below 130/80 mmHg in the clinic and at home within six months | 2026-10-19 | completed | 124/76 in the clinic; home average 126/78 |
| A1c below 7% within six to nine months, without low blood sugar | 2026-10-19 | completed | 6.9% at seven months; no low blood sugar |
| Urine albumin-to-creatinine ratio lower by at least 30% within six months | 2026-10-19 | completed | 88 to 96 mg/g at baseline; 41 mg/g at seven months |
| Food and utility needs met through benefits, and a dependable way to reach every visit and laboratory test | 2026-10-19 | active | SNAP and energy assistance in place; rides arranged for every visit after one missed laboratory check; transportation still uncertain on some days |
| LDL cholesterol below 70 mg/dL | 2026-10-19 | active | 146 to 80 mg/dL on atorvastatin; recheck with the yearly panel |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Consent-based, trauma-informed care at every visit: explain each examination, test and procedure beforehand (what it is, why, what it involves, the alternatives, including not doing it), ask her agreement and record it, offer a chaperone or companion of her choosing, let her stop at any time, never perform an unplanned procedure, and keep the plan in writing; written consent for any procedure beyond routine tests | completed | GL-SAMHSA-TIP57-2014, GL-AMA-CONSENT, GL-ACOG-CONSENT-2021 |
| Nephrology consultation by telehealth from the health center, with the community health worker present, for albumin in the urine and reduced kidney function in a woman with an old kidney injury, new diabetes and high blood pressure readings | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026 |
| Blood pressure: a validated home monitor with a large cuff, provided by the health center, with readings twice a day for seven days to confirm the diagnosis; less salt, using foods she can get; recheck in two weeks | completed | GL-AHA-HTN-2025, GL-CMID-2026 |
| Diabetes: metformin extended-release once daily, an A1c every three months until at goal, diabetes self-management education in a group class at the health center, and no medicine that can cause low blood sugar | completed | GL-ADA-2026, GL-CMID-2026 |
| Kidneys: repeat the urine albumin test, a kidney ultrasound with the consultation, no ibuprofen or naproxen, and kidney function and potassium checks after any blood pressure or kidney medicine is started | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026 |
| Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks, a baseline ECG, and TSH at diagnosis | completed | GL-ADA-2026, GL-AHA-HTN-2025, GL-CMID-2026 |
| Eyes and feet: retinal photographs in the clinic, so that no separate trip is needed; a comprehensive foot examination yearly; daily foot checks at home, callus care at the health center and well-fitting shoes | completed | GL-ADA-RETFOOT-2026 |
| Social needs, with the community health worker: the AHC health-related social needs screen at intake and every few months; help applying for SNAP and the Low Income Home Energy Assistance Program; the health center's food pantry and produce program; 211 for other local help; rides arranged for every visit and laboratory test; the sliding-fee scale; 90-day medicine supplies at the discount pharmacy, and phone visits when travel is not possible | completed | GL-AHC-HRSN, GL-ADA-POP-2026, GL-SNAP, GL-LIHEAP |
| Shared decisions and the team: Dr. Batiste-Hill, a nurse, the community health worker and the pharmacist review the plan with her; medicines chosen for cost, once-daily dosing and her preferences; she decides what she accepts | completed | GL-ADA-2026, GL-ACOG-CONSENT-2021 |
| Mood and stress: PHQ-9 at intake and at four months, asked privately; counseling offered at her choice | completed | GL-USPSTF-DEP-2023, GL-CMID-2026 |
| Vaccines: pneumococcal, hepatitis B and Tdap offered, explained and given only with her agreement; influenza and COVID-19 each autumn | completed | GL-CDC-IMZ-2026 |
| On the consultant's advice: amlodipine 5 mg with benazepril 20 mg in one daily capsule and dapagliflozin 10 mg daily with sick-day rules; potassium and creatinine one to two weeks after starting; urine albumin again at three to four months; blood pressure goal below 130/80; review of kidney treatment by telehealth if albumin stays raised | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026, GL-AHA-HTN-2025 |
| Laboratory checks on the days she is already at the health center, with a ride arranged in advance for any extra check; home blood draw by the mobile phlebotomy service when no ride can be found | completed | GL-ADA-POP-2026, GL-AHC-HRSN |
| Metformin extended-release increased to 1,500 mg with the evening meal, because the A1c was still above goal | completed | GL-ADA-2026, GL-CMID-2026 |
Planned encounters
- 2026-03-09 — Establishing care at the rural community health center for high blood pressure readings, thirst and frequent urination, leg and back aching, and reduced vision in the left eye since an old injury, with consent-based, trauma-informed care and a social needs screen (ENC-001)
- 2026-03-23 — Two-week review of home blood pressure readings and the repeat urine test, with a kidney ultrasound and a nephrology telehealth consultation from the health center (ENC-002)
- 2026-05-04 — Six-week review: blood pressure, kidney function and potassium after the new medicines, lipids, retinal photographs, and benefits (ENC-003)
- 2026-07-13 — Four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose (ENC-004)
- 2026-09-14 — Periodic adult preventive visit (ENC-006)
- 2026-10-19 — Seven-month review: A1c, urine albumin, kidney function, seasonal and age-50 vaccines, screening results, and plans for the winter (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Nephrology referral
- Nephrology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Nephrology referral (XML)
- Nephrology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the confirmation of hypertension by home readings, the CKD G2 A2 classification with a scarred kidney, the single-pill amlodipine-benazepril, dapagliflozin and its sick-day rules, atorvastatin intensity, the eGFR without a race term, and the consent documentation at each visit. |
| provenance review | not_started | Sources: the National Women's History Museum, the SNCC Digital Gateway, PBS, her own 1964 testimony (American RadioWorks), The Conversation, the Equal Justice Initiative, the Mississippi Free Press, WCBI, the UMKC Women's Center, and Fannie Lou Hamer's America. The Smithsonian and Library of Congress pages could not be fetched. |
| safe messaging review | not_started | The sterilization and the beating are recorded as sensitive, plainly and without graphic detail. No mental health claim is made; mood screening is synthetic and below the threshold for a safety assessment. Her mistrust is presented as earned, and her refusals are respected, not labeled. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.